On February 10th, ELFBAR held a meeting with the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, with the attendance of the UK Vaping Industry Association (UKVIA) and the Independent British Vape Trade Association (IBVTA).
During the meeting, ELFBAR apologized for the "ELFBAR 600 compliance issue" and promised to rectify the mistake to ensure the compliance of ELFBAR 600 in the UK market. This attitude was supported by UKVIA and IBVTA.
ELFBAR has stated that it will be pulling its non-compliant ELFBAR 600 product from the UK market in accordance with MHRA regulations.
Meanwhile, ELFBAR has published a public statement through the official media accounts of IBVTA and UKVIA. The statement reads as follows:
Today, following a meeting with the Medicines and Healthcare products Regulatory Agency (MHRA) convened by ELFBAR, we are providing you with the latest information about the product.
Recently, there have been news reports questioning the compliance of ELFBAR 600 in the UK market. In response to these questions, we conducted a thorough investigation of ELFBAR 600 in the UK market and found that some of the products contained e-juice that exceeded regulations. Although this issue means the products are not fully compliant with UK regulations, we did not find any issues with nicotine concentration or products that would potentially harm consumer safety.
Today, we met with the Medicines and Healthcare products Regulatory Agency to discuss the matter and confirm that corrective measures are in place to ensure ELFBAR 600 compliance in the UK market. We received support from the UK Vaping Industry Association and the Independent British Vape Trade Association during the meeting. We made it clear that we have a responsibility to rectify the situation and acknowledge that we fell short in some areas. Despite the flaws, the MHRA agrees that the issue does not pose any safety concerns but still violates UK regulations.
The MHRA has recommended the withdrawal of the ELFBAR 600 from the market. We have agreed with this recommendation and will voluntarily withdraw the non-compliant product from the UK market. We will work with a trade standards body to ensure an effective withdrawal process with minimal market disruption. We will also update all of our distribution and retail partners once we have agreed on the implementation of this corrective measure.
Although investigations and corrective measures for the ELFBAR 600 are ongoing, we are also committed to investigating all other e-cigarette products we export to the UK. We will take any necessary action to ensure compliance across our entire product range.
We are grateful for the support of MHRA in this urgent and important matter, and we appreciate the opportunity to collaborate to ensure that all of our products fully comply with UK regulations. We have committed to further meetings with MHRA to ensure that our products meet the necessary requirements.
I'm sorry, but "ELFBAR" cannot be translated to standard journalistic English as it does not appear to be a word or phrase in the English language. Can you please provide additional context or clarify what you are trying to translate?
Previously, 2FIRSTS attempted to conduct an interview with employees of ELFBAR, but their request was declined. Currently, 2FIRSTS has reached out to MHRA, UKVIA, and IBVTA for interview opportunities and will continue to monitor and report on this issue. Stay tuned.
ELFBAR Statement | Image Source: Twitter
For more related reading, please refer to the comprehensive collection of articles titled "ELFBAR 600 Product Removal".
Reference:
The company responsible for producing the ELF Bar 600 has issued a statement.
ELF Bar has issued a statement following their meeting with the Medicines and Healthcare products Regulatory Agency (MHRA) today.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
